HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Over 13 years' experience in both finance and healthcare, covering clinic operations, investment and equity research in both China and overseas.

China Traditional Chinese Medicine (570.HK) - Short-Term Performance Pressure Is Hard to Avoid

China Resources Medical - Hard to Earn High Profits Due to Poor Business Model and Policy Risk

Micro-Tech Nanjing (688029.CH) - Potential for Reversals Despite Short-Term Pressure on Performance

Pre-IPO MicroPort NeuroTech - The Industry, the Business and the Concern

JD Health (6618.HK) - Logic Change Due to the New Policy?

Ping An Healthcare and Technology (1833.HK) - Untenable Business Model Worsen the Logic and Outlook

Gravity Works As WeWork Doesn't; Now Plan B

Equity Bottom-Up

<ul>
<li>Through perfect partnership system, Gushengtang locks in the scarce TCM physicians, and then quickly establishes/merges offline medical institutions to occupy the market. Such development mode works well so far.</li>
<li>The challenges are the risks of losing talents to competitors and the weak sales of healthcare products leading to lower profitability. </li>
<li>Gushengtang is in an industry that receives government encouragement/preferential policies. The 2022 revenue growth forecast could fall back to about 25% considering the pandemic/lockdown. The EPS could narrowly turn positive.</li>
</ul>


Through perfect partnership system, Gushengtang locks in the scarce TCM physicians, and then quickly establishes/merges offline medical institutions to occupy the market. Such development mode works well so far.
The challenges are the risks of losing talents to competitors and the weak sales of healthcare products leading to lower profitability. 
Gushengtang is in an industry that receives government encouragement/preferential policies. The 2022 revenue growth forecast could fall back to about 25% considering the pandemic/lockdown. The EPS could narrowly turn positive.


Gushengtang (2273.HK) - The Development Momentum Is Good, but There Are Also Challenges